We treat weight gain as a medical issue, not a personal failure
[9] [12] Other significant risks include acute pancreatitis (patients should report severe, persistent abdominal pain with or without vomiting), gallbladder disease (watch for right upper quadrant pain, fever, jaundice), acute kidney injury (particularly with severe gastrointestinal symptoms causing dehydration), and hypoglycemia when used with insulin or sulfonylureas
Results announced in September 2025 and published in The Lancet in February 2026 demonstrated orforglipron's superiority over oral semaglutide on both HbA1c reduction (approximately 2.2 vs 1.4 percentage points) and weight loss (approximately 9.2% vs 5.3%)
The timing is notable, as Congress and state Medicaid leaders brace for the potential of more significant cuts to federal funding for Medicaid in the upcoming federal budget reconciliation process
Yes, IGF-1 LR3 enhances collagen synthesis and cellular regeneration in human-derived muscle and tendon models, supporting faster healing and reduced recovery time after physical stress
Phase Therapeutic range Weeks Weeks 17-20 Weekly Dose 9 mg Notes Phase 3 target dose for many TRIUMPH arms
